NUWE Stock Overview
A medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nuwellis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.24 |
| 52 Week High | US$3.83 |
| 52 Week Low | US$0.13 |
| Beta | 0.30 |
| 1 Month Change | 32.78% |
| 3 Month Change | -49.46% |
| 1 Year Change | -91.73% |
| 3 Year Change | -99.94% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| NUWE | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -15.8% | -0.6% | -0.6% |
| 1Y | -91.7% | 2.1% | 22.4% |
Return vs Industry: NUWE underperformed the US Medical Equipment industry which returned 2.1% over the past year.
Return vs Market: NUWE underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| NUWE volatility | |
|---|---|
| NUWE Average Weekly Movement | 31.2% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NUWE's share price has been volatile over the past 3 months.
Volatility Over Time: NUWE's weekly volatility has increased from 20% to 31% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 59 | Nestor Jaramillo | www.nuwellis.com |
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.
Nuwellis, Inc. Fundamentals Summary
| NUWE fundamental statistics | |
|---|---|
| Market cap | US$4.27m |
| Earnings (TTM) | -US$19.93m |
| Revenue (TTM) | US$8.90m |
0.5x
P/S Ratio-0.2x
P/E RatioIs NUWE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUWE income statement (TTM) | |
|---|---|
| Revenue | US$8.90m |
| Cost of Revenue | US$3.79m |
| Gross Profit | US$5.11m |
| Other Expenses | US$25.04m |
| Earnings | -US$19.93m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 57.41% |
| Net Profit Margin | -224.07% |
| Debt/Equity Ratio | 0% |
How did NUWE perform over the long term?
See historical performance and comparison